Biogen

UCB and Biogen announced positive Phase III PHOENYCS GO study results for dapirolizumab pegol, a treatment for moderate-to-severe systemic lupus erythematosus (SLE), showing improvement in disease activity at week 48. The drug, which blocks B cell activation, also reduced disease flares. A second Phase III study, PHOENYCS FLY, will start in 2024.

Biogen and UCB's anti-CD40L candidate, dapirolizumab pegol, met primary endpoint in phase III lupus trial, showing improvement over placebo and standard of care at 48 weeks.

Eli Lilly's Alzheimer's drug, donanemab, approved by Japan's health ministry, offering another treatment option after Eisai and Biogen's Leqembi. Kisunla, sold in the U.S., slows memory and thinking problems by 29% but has risks of brain swelling and bleeding. Unlike Leqembi, Kisunla has finite dosing, allowing patients to stop treatment when amyloid plaques are no longer visible.

UCB and Biogen's phase 3 trial of dapirolizumab pegol for systemic lupus erythematosus (SLE) was successful, with clinical improvement in primary and secondary endpoints. A second trial, PHOENICS FLY, is expected to start before year-end. If approved, dapirolizumab pegol could offer a new treatment for SLE, a chronic autoimmune disease affecting multiple organ systems.

The biotechnology market, valued at USD 1023.92 Million in 2022, is projected to reach USD 10129.16 Billion by 2030 with a CAGR of 29.00%. Driven by personalized medicine, R&D advancements, and investments, key players like Roche and Thermo Fisher Scientific Inc. are leading innovation. Segmented by technology, application, and end-user, the market spans healthcare, agriculture, and industrial biotechnology, among others.

Article sent to my@email.address. All fields required; separate multiple recipients with a semicolon. Active subscribers access full article; others directed to abstract.

UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus (SLE), with plans to advance to a second Phase 3 study in 2024. Dapirolizumab pegol, a humanized, Fc-free polyethylene glycol-conjugated antigen-binding fragment, targets the CD40L pathway to reduce B cell activation and autoantibody production, offering a potential new treatment option for SLE.

Biogen and UCB's drug candidate dapirolizumab pegol met primary efficacy endpoint in Phase III PHOENYCS GO study for systemic lupus erythematosus, showing greater improvement of moderate-to-severe disease activity at 48 weeks versus placebo. The treatment also demonstrated clinical improvements in key secondary endpoints. Safety profile was consistent with previous studies. Biogen and UCB plan to initiate another Phase III study, PHOENYCS FLY, this year. Full results to be presented at a medical congress.